What endocrine screening and management should be performed in patients with Marfan syndrome?

Endocrine Screening and Management in Marfan Syndrome

No routine endocrine screening is recommended for patients with Marfan syndrome, as endocrine abnormalities are not a cardinal feature of this connective tissue disorder. The diagnosis and management of Marfan syndrome focus on cardiovascular, ocular, and skeletal manifestations, with no specific endocrine panels required 1.

Core Diagnostic and Surveillance Approach

The multidisciplinary evaluation of Marfan syndrome should prioritize the following systems, none of which include routine endocrine assessment:

Cardiovascular Surveillance (Primary Focus)

• Obtain transthoracic echocardiography (TTE) at initial diagnosis to measure aortic root diameter at the sinuses of Valsalva and assess for aortic regurgitation and mitral valve prolapse 2, 1
• Repeat TTE at 6 months to determine the rate of aortic growth; if stable, perform annual surveillance thereafter 2, 1
• After initial TTE, obtain CT or MRI of the thoracic aorta to confirm aortic diameters and assess the entire aortic tree 2, 1
• Following aortic root replacement, perform annual MRI or CT surveillance of the thoracic aorta to evaluate for distal thoracic aortic disease; if normal and unchanged after 2 years, imaging can be performed every other year 2

Genetic Testing

• Order FBN1 gene sequencing as the first-line genetic test to identify pathogenic fibrillin-1 mutations 1
• Recognize that approximately 10% of patients meeting clinical criteria will have no detectable FBN1 mutation, so negative genetic testing does not exclude the diagnosis 3, 1
• If FBN1 testing is negative, perform targeted testing of TGFBR1 and TGFBR2 to identify Marfan-type (MFS2) or Loeys-Dietz syndrome with overlapping phenotypes 1

Ophthalmologic Assessment

• Perform slit-lamp examination with fully dilated pupils by an ophthalmologist experienced in connective tissue disorders to detect ectopia lentis 1
• Ectopia lentis is both sensitive and fairly specific for Marfan syndrome and helps differentiate it from Loeys-Dietz syndrome 1

Skeletal Examination

• Conduct thorough physical examination for skeletal features including arachnodactyly, dolichostenomelia, pectus deformities, scoliosis, and joint laxity, which contribute to the systemic score in the revised Ghent nosology 1

When to Consider Limited Laboratory Testing

For Menstrual Irregularities (If Present)

• Order complete blood count (CBC) to screen for anemia when abnormal uterine bleeding is suspected 1
• Measure thyroid-stimulating hormone (TSH) to exclude thyroid dysfunction as a cause of menstrual disturbances 1
• These tests address symptoms, not Marfan syndrome itself, and should only be ordered when clinically indicated 1

For Joint Pain (If Inflammatory Features Present)

• Consider inflammatory markers (ESR, CRP) and rheumatologic work-up only if clinical signs suggest inflammatory arthritis such as joint swelling, warmth, or morning stiffness 1
• These tests are not part of routine Marfan assessment and should be reserved for patients with specific inflammatory symptoms 1

Critical Pitfalls to Avoid

• Do not order extensive laboratory panels for Marfan evaluation, as they do not contribute to diagnosis and may lead to unnecessary testing 1
• Do not rely exclusively on genetic testing; approximately 10% of definitively diagnosed patients lack an identifiable FBN1 mutation, underscoring the importance of clinical criteria 3, 1
• Ensure multidisciplinary evaluation involving cardiology (TTE/CT/MRI) and ophthalmology (slit-lamp exam) as essential components of the diagnostic work-up 1, 4
• Systematically obtain family history of first-degree relatives with Marfan syndrome, as this significantly influences diagnostic criteria 1

Why Endocrine Screening Is Not Indicated

Marfan syndrome is caused by mutations in the FBN1 gene encoding fibrillin-1, a glycoprotein in the extracellular matrix 5. The pathophysiology involves weakening of supportive tissues and dysregulation of transforming growth factor-β (TGF-β), affecting cardiovascular, skeletal, ocular, pulmonary, and dural systems 5, 6. Endocrine manifestations are not part of the cardinal features of Marfan syndrome, and no guidelines recommend routine endocrine screening 2, 5, 3, 1.

The diagnosis relies on the revised Ghent nosology, which incorporates genetic testing, systemic score, ectopia lentis, and family history—none of which include endocrine parameters 5, 3. Prognosis is primarily determined by progressive aortic dilation leading to dissection or rupture, which are the major causes of death 5, 4. Therefore, cardiovascular surveillance remains the cornerstone of management, with no role for routine endocrine evaluation 2, 1.